Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 26, Issue 1, 2012, Pages 1-7

  Lauterbach, Edward C ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; antidepressants; antipsychotics; gene expression; mRNA; risk

Indexed keywords

AMYLOID BETA PROTEIN; ATYPICAL ANTIPSYCHOTIC AGENT; CASPASE; CHEMOKINE RECEPTOR CCR2; CHLORPROMAZINE; CLUSTERIN; DIAZEPAM; ENDOTHELIN CONVERTING ENZYME; ETANERCEPT; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; INTERLEUKIN 1BETA; LITHIUM; MAPROTILINE; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHATASE; PRION PROTEIN; PROTEIN BAX; PSYCHOTROPIC AGENT; RISPERIDONE; SORTILIN; THYROID HORMONE RECEPTOR; TRANSFERRIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ATTENUATION; BIPOLAR DISORDER; BRAIN REGION; CELL MIGRATION; CHOLESTEROL METABOLISM; CODON; DOWN REGULATION; DRUG EFFECT; ENDOCYTOSIS; FIBROSIS; FRONTAL CORTEX; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE SURVEY; HIPPOCAMPUS; HUMAN; MEDLINE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TRANSCRIPTOMICS; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; FLUOXETINE; GENOTYPE; HALOPERIDOL; HUMANS; LITHIUM; MICE; MUTATION; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; RATS; RISK; TRANSCRIPTOME;

EID: 84857784726     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318214b7d0     Document Type: Review

References (73)

1. Lauterbach EC, Shillcutt SD, Victoroff J, et al. Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications. J Neuropsychiatry Clin Neurosci. 2010;22:130-154.
2. Bertram L, McQueen MB, Mullin K, et al. Systematic metaanalyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17-23. Available at: http://www.alzgene.org/, accessed June 4, 2010, updated October 11, 2010. (Pubitemid 46026496)
3. Miller BH, Schultz LE, Gulati A, et al. Genetic regulation of behavioral and neuronal responses to fluoxetine. Neuropsychopharmacology. 2008;33:1312-1322. (Pubitemid 351521706)
4. Fatemi SH, Reutiman TJ, Folsom TD, et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsycho-pharmacology. 2006;31:1888-1899.
5. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41: 1088-1093.
6. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094-1099.
7. Seshadri S, Fitzpatrick AL, Ikram MA, et al. CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832-1840.
8. Nuutinen T, Suuronen T, Kauppinen A, et al. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev. 2009; 61:89-104.
9. Liang X, Slifer M, Martin ER, et al. Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10. Hum Mutat. 2009;30:463-471.
10. Yang L, Lu R, Jiang L, et al. Expression and genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A polymorphism in sporadic Alzheimer's disease in a Southern China population. Brain Res. 2009;1247:178-181.
11. Fillit H, Ding WH, Buee L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett. 1991;129:318-320.
12. Tarkowski E, Blennow K, Wallin A, et al. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999;19:223-230. (Pubitemid 29409451)
13. Solerte SB, Cravello L, Ferrari E, et al. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann N Y Acad Sci. 2000;917: 331-340.
14. Anton Alvarez X, Sampedro C, Cacabelos R, et al. Reduced TNF-alpha and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent Cerebrolysin. Int J Neuropsychopharmacol. 2009;12: 867-872.
15. Cheng X, Yang L, He P, et al. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J Alzheimers Dis. 2010;19:621-630.
16. McAlpine FE, Lee JK, Harms AS, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009;34:163-177.
17. Tobinick E, Gross H, Weinberger A, et al. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med Gen Med. 2006;8:25.
18. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65:395-407. (Pubitemid 351519889)
19. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432-438. (Pubitemid 46559828)
20. Namekata K, Oyama F, Imagawa M, et al. Human transferrin (Tf): a single mutation at codon 570 determines Tf C1 or Tf C2 variant. Hum Genet. 1997;100:457-458. (Pubitemid 27386857)
21. Robson KJ, Lehmann DJ, Wimhurst VL, et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet. 2004;41:261-265. (Pubitemid 38496768)
22. Saetre P, Emilsson L, Axelsson E, et al. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry. 2007;7:46.
23. Li Y, Grupe A, Rowland C, et al. Evidence that common variation in NEDD9 is associated with susceptibility to lateonset Alzheimer's and Parkinson's disease. Hum Mol Genet. 2008;17:759-767. (Pubitemid 351292264)
24. Viswanathan J, Mäkinen P, Helisalmi S, et al. An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:747-750.
25. Fenoglio C, Galimberti D, Cortini F, et al. Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J Alzheimers Dis. 2009;18:603-612.
26. Brouwers N, Nuytemans K, van der Zee J, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64:1436-1446. (Pubitemid 47572667)
27. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920-924. (Pubitemid 44285947)
28. Rademakers R, Cruts M, Dermaut B, et al. Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8cM interval. Mol Psychiatry. 2002;7:1064-1074. (Pubitemid 36044265)
29. Carecchio M, Fenoglio C, De Riz M, et al. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. J Neurol Sci. 2009;287:291-293.
30. Kelley BJ, Haidar W, Boeve BF, et al. Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol. 2010;67:171-177.
31. Licastro F, Veglia F, Chiappelli M, et al. A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer's disease. Neurobiol Aging. 2004;25:1017-1022. (Pubitemid 38798063)
32. Craig D, Hart DJ, McCool K, et al. The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia. Ann Neurol. 2004;56:121-124. (Pubitemid 38857367)
33. McCulley MC, Day IN, Holmes C. Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2004;124B:50-53. (Pubitemid 38031592)
34. Casamenti F, Prosperi C, Scali C, et al. Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease. Neuroscience. 1999;91:831-842. (Pubitemid 29225619)
35. Holmes C, El-Okl M, Williams AL, et al. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74:788-789. (Pubitemid 36628295)
36. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience. 1994;61:745-754. (Pubitemid 24291917)
37. Cacabelos R, Alvarez XA, Fernández-Novoa L, et al. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol. 1994;16:141-151.
38. Song XQ, Lv LX, Li WQ, et al. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry. 2009;65:481-488.
39. Suzuki E, Shintani F, Kanba S, et al. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci Lett. 1996;215:201-204. (Pubitemid 26323461)
40. Sutherland MK, Wong L, Somerville MJ, et al. Reduction of thyroid hormone receptor c-ERB A alpha mRNA levels in the hippocampus of Alzheimer as compared to Huntington brain. Neurobiol Aging. 1992;13:301-312.
41. Xu S, Zhong M, Zhang L, et al. Overexpression of Tfam protects mitochondria against beta-amyloid-induced oxidative damage in SH-SY5Y cells. FEBS J. 2009;276:3800-3809.
42. Alvarez V, Corao AI, Alonso-Montes C, et al. Mitochondrial transcription factor A (TFAM) gene variation and risk of lateonset Alzheimer's disease. J Alzheimers Dis. 2008;13:275-280. (Pubitemid 352039031)
43. Du Y, Dodel RC, Eastwood BJ, et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology. 2000;55:480-483. (Pubitemid 30648897)
44. Grimaldi LM, Casadei VM, Ferri C, et al. Association of earlyonset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol. 2000;47:361-365. (Pubitemid 30141846)
45. Nicoll JA, Mrak RE, Graham DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol. 2000;47:365-368. (Pubitemid 30141847)
46. Murphy GM Jr, Claassen JD, DeVoss JJ, et al. Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha -889 z.ast;1 allele. Neurology. 2001;56:1595-1597. (Pubitemid 32532280)
47. Kölsch H, Ptok U, Bagli M, et al. Gene polymorphisms of interleukin-1alpha influence the course of Alzheimer's disease. Ann Neurol. 2001;49:818-819. (Pubitemid 32530257)
48. Choi DS, Wang D, Yu GQ, et al. PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci U S A. 2006;103:8215-8520.
49. Mouillet-Richard S, Ermonval M, Chebassier C, et al. Signal transduction through prion protein. Science. 2000;289:1925-1928.
50. Steele AD, Emsley JG, Ozdinler PH, et al. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci U S A. 2006;103:3416-3421. (Pubitemid 43346483)
51. Bounhar Y, Zhang Y, Goodyer CG, et al. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem. 2001;276:39145-39149.
52. Laurén J, Gimbel DA, Nygaard HB, et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloidbeta oligomers. Nature. 2009;457:1128-1132.
53. Berr C, Richard F, Dufouil C, et al. Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology. 1998;51:734-737. (Pubitemid 28449251)
54. Croes EA, Dermaut B, Houwing-Duistermaat JJ, et al. Early cognitive decline is associated with prion protein codon 129 polymorphism. Ann Neurol. 2003;54:275-276. (Pubitemid 36909632)
55. Dermaut B, Croes EA, Rademakers R, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol. 2003;53:409-412. (Pubitemid 36258648)
56. Riemenschneider M, Klopp N, Xiang W, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology. 2004;63:364-366. (Pubitemid 38971146)
57. He G, Luo W, Li P, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature. 2010; 467:95-98.
58. Avramopoulos D. Genetics of Alzheimer's disease: recent advances. Genome Med. 2009;1:34.
59. Zetzsche T, Rujescu D, Hardy J, et al. Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn. 2010; 10:667-690.
60. Hardy J, Williams J. Identification of Alzheimer risk factors through whole-genome analysis. Arch Neurol. 2010;67:663-664.
61. Corneveaux JJ, Myers AJ, Allen AN, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010;19:3295-3301.
62. Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One. 2010;5:e13950.
63. Vik-Mo AO, Fernø J, Skrede S, et al. Psychotropic drugs upregulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol. 2009;9:10.
64. Nuutinen T, Suuronen T, Kauppinen A, et al. Valproic acid stimulates clusterin expression in human astrocytes: implications for Alzheimer's disease. Neurosci Lett. 2010;475:64-68.
65. Gräff J, Mansuy IM. Epigenetic dysregulation in cognitive disorders. Eur J Neurosci. 2009;30:1-8.
66. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry. 2000; 15(suppl 1):S2-S4.
67. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's coordinating center. Neurology. 2005;64:494-500. (Pubitemid 40189869)
68. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147:1049-1051. (Pubitemid 20257519)
69. Pritchard AL, Pritchard CW, Bentham P, et al. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;26:257-260.
70. Pritchard AL, Harris J, Pritchard CW, et al. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol Aging. 2008;29: 341-347. (Pubitemid 351215579)
71. Pritchard AL, Pritchard CW, Bentham P, et al. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24:201-206. (Pubitemid 47312670)
72. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889-898. (Pubitemid 351944940)
73. Lauterbach EC, Victoroff J, Coburn KL, et al. Psychophar-macological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci. 2010;22:8-18.